Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
55111-0154-05 55111-0154 Ondansetron Hydrochloride ONDANSETRON 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 26, 2006 In Use
72578-0166-01 72578-0166 Dexamethasone Dexamethasone 1.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 13, 2024 In Use
75921-0459-10 75921-0459 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 25, 2007 In Use
00093-7600-57 00093-7600 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 12, 2013 Jan 31, 2019 In Use
60505-3802-07 60505-3802 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
65862-0149-90 65862-0149 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Oct 30, 2007 In Use
43975-0254-05 43975-0254 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Jul 13, 2016 In Use
54569-0811-03 54569-0811 Estrogens, Conjugated Premarin 0.3 mg/1 Hormonal Therapy Estrogen Oral Jan 1, 2006 In Use
70518-4293-07 70518-4293 PREDNISONE Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug 25, 2026 In Use
00006-4109-06 00006-4109 Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant GARDASIL 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL Ancillary Therapy Protective Agent HPV Vaccine Intramuscular Jun 8, 2006 May 6, 2011 In Use
69097-0577-73 69097-0577 nilotinib NILCEYA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
33261-0740-28 33261-0740 Medroxyprogesterone Acetate Medroxyprogesterone Acetate 5.0 mg/1 Hormonal Therapy Progestin Oral Dec 3, 1996 In Use
71335-2753-06 71335-2753 PredniSONE PredniSONE Tablets, USP, 5 mg 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct 3, 2025 In Use
61703-0343-18 61703-0343 Mitoxantrone Mitoxantrone 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous Apr 11, 2006 In Use
12634-0184-85 12634-0184 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jan 1, 1999 In Use
57894-0510-01 57894-0510 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) RYBREVANT FASPRO 1600.0 mg/10mL, 20000.0 mg/10mL Immunotherapy Monoclonal Antibody EGFR, MET Subcutaneous Dec 19, 2025 In Use
70518-3600-03 70518-3600 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral May 1, 2023 In Use
42658-0021-91 42658-0021 Daunorubicin hydrochloride Daunorubicin Hydrochloride 5.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jan 15, 2023 In Use
20536-0322-01 20536-0322 Vincristine Sulfate Marqibo Chemotherapy Antimitotic Agent Vinca Alkaloid Jan 14, 2013 Oct 26, 2020 In Use
70518-0306-01 70518-0306 Prednisone Prednisone 50.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 9, 2017 Jun 16, 2021 In Use
16729-0231-64 16729-0231 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Jul 30, 2012 Jun 21, 2019 In Use
16729-0295-33 16729-0295 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound INTRACAVERNOUS, Intravenous Sep 19, 2017 In Use
00093-7602-57 00093-7602 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 12, 2013 Oct 31, 2018 In Use
50242-0060-10 50242-0060 Bevacizumab Avastin 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 1, 2019 Jan 31, 2023 In Use
71335-2753-05 71335-2753 PredniSONE PredniSONE Tablets, USP, 5 mg 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct 3, 2025 In Use

Found 12611 results — Export these results